Antitumor effects of 32P‑chromic‑poly (L‑lactide) brachytherapy in nude mice with human prostate cancer

Sun,Liujing; Zhu,Xishan; Xu,Longbao; Wang,Zizheng; Shao,Guoqiang; Zhao,Jun

doi:10.3892/ol.2013.1443

Antitumor effects of 32P‑chromic‑poly (L‑lactide) brachytherapy in nude mice with human prostate cancer

Authors:
- Liujing Sun
- Xishan Zhu
- Longbao Xu
- Zizheng Wang
- Guoqiang Shao
- Jun Zhao
View Affiliations

Affiliations: Department of Urinary Surgery, Changzhou No. 3 People's Hospital, Changzhou, Jiangsu 213000, P.R. China, Department of Nuclear Medicine, Changzhou No. 2 People's Hospital, Changzhou, Jiangsu 213000, P.R. China, Department of Clinical Nuclear Medicine, Nanjing No. 1 Hospital, Nanjing, Jiangsu 210006, P.R. China
Published online on: July 3, 2013 https://doi.org/10.3892/ol.2013.1443
Pages: 687-692

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to investigate the antitumor effects and tissue distribution of 32P‑chromic‑poly (L‑lactide) (32P‑CP‑PLLA) in nude mice with human prostate cancer. Tumor models were obtained by transplantation of PC‑3M tumor cells into male BALB/c nude mice. Animals were randomly divided into control, 32P‑chromic phosphate (32P‑CP) colloid and 32P‑CP‑PLLA groups (all n=20). A series of indices were investigated, including apoptosis of tumor cells, rate of apoptosis, expression of caspase 3 and 8, biodistribution and intratumoral concentration of 32P‑CP‑PLLA, intensity of radioactivity, tumor volume and microvessel density (MVD). Highly concentrated radioactivity of 32P‑CP‑PLLA in the tumor mass was detected by single photon emission computed tomography (SPECT) scanning. The residual activities of the 32P‑CP‑PLLA and 32P‑CP colloid groups were 3.02±0.32 and 1.76±0.31 MBq, respectively, on day 14 following treatment. The tumor inhibition rates were 67.24±3.55 and 55.92±7.65%, respectively (P<0.01). Necrotic changes, in conjunction with apoptosis, were observed in the treatment group. MVD values for the 32P‑CP‑PLLA and 32P‑CP colloid groups were 28.24±10.07 and 36.15±11.06, respectively. 32P‑CP‑PLLA showed an excellent capacity for killing tumor cells, inducing apoptosis and inhibiting angiogenesis.

View Figures

View References

1	Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2009. CA Cancer J Clin. 59:225–249. 2009. View Article : Google Scholar
2	Hummel S, Simpson EL, Hemingway P, et al: Intensity-modulated radiotherapy for the treatment of prostate cancer: a systematic review and economic evaluation. Health Technol Assess. 14:1–108. iii–iv
3	Alicikus ZA, Yamada Y, Zhang Z, et al: Ten-year outcomes of high-dose, intensity-modulated radiotherapy for localized prostate cancer. Cancer. 117:1429–1437
4	Michalski JM, Winter K, Purdy JA, et al: Toxicity after three-dimensional radiotherapy for prostate cancer on RTOG 9406 dose Level V. Int J Radiat Oncol Biol Phys. 62:706–713. 2005. View Article : Google Scholar : PubMed/NCBI
5	Zelefsky MJ, Kuban DA, Levy LB, et al: Multi-institutional analysis of long-term outcome for stages T1–T2 prostate cancer treated with permanent seed implantation. Int J Radiat Oncol Biol Phys. 67:327–333. 2007.PubMed/NCBI
6	Tward JD, Lee CM, Pappas LM, et al: Survival of men with clinically localized prostate cancer treated with prostatectomy, brachytherapy or no definitive treatment: impact of age at diagnosis. Cancer. 107:2392–2400. 2006. View Article : Google Scholar
7	Chauveinc L, Osseili A, Flam T, et al: Iodin 125 seed migration after prostate brachytherapy: a study of 170 patients. Cancer Radiother. 8:211–216. 2004.(In French).
8	Moosmayer D, Berndorff D, Chang CH, et al: Bispecific antibody pretargeting of tumor neovasculature for improved systemic radiotherapy of solid tumors. Clin Cancer Res. 12:5587–5595. 2006. View Article : Google Scholar : PubMed/NCBI
9	Kao J, Stone NN, Lavaf A, et al: (125)I monotherapy using D90 implant doses of 180 Gy or greater. Int J Radiat Oncol Biol Phys. 70:96–101. 2008. View Article : Google Scholar : PubMed/NCBI
10	Taira AV, Merrick GS, Butler WM, et al: Long-term outcome for clinically localized prostate cancer treated with permanent interstitial brachytherapy. Int J Radiat Oncol Biol Phys. 79:1336–1342. 2011.PubMed/NCBI
11	Stone NN, Potters L, Davis BJ, et al: Multicenter analysis of effect of high biologic effective dose on biochemical failure and survival outcomes in patients with Gleason score 7–10 prostate cancer treated with permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys. 73:341–346. 2009.PubMed/NCBI
12	Mortazavi SM, Asadollahi S, Farzan M, et al: (32)P colloid radiosynovectomy in treatment of chronic haemophilic synovitis: Iran experience. Haemophilia. 13:182–188. 2007. View Article : Google Scholar : PubMed/NCBI
13	Gao W, Liu L, Liu ZY, et al: Intratumoral injection of 32P-chromic phosphate in the treatment of implanted pancreatic carcinoma. Cancer Biother Radiopharm. 25:215–224. 2010. View Article : Google Scholar : PubMed/NCBI
14	Zubillaga MB, Boccio JR, Nicolini JO, et al: Use of colloids of chromic [32P] phosphate in treatment of solid tumors. Nucl Med Biol. 23:907–910. 1996.
15	Alimi KA, Firusian N and Dempke W: Effects of intralesional 32-P chromic phosphate in refractory patients with head and neck tumours. Anticancer Res. 27:2997–3000. 2007.PubMed/NCBI
16	Zubillaga MB, Boccio JR, Nicolini JO, et al: Great particles [32P]chromic phosphate for treatment of solid tumors. Acta Physiol Pharmacol Ther Latinoam. 46:103–110. 1996.
17	Zubillaga M, Boccio J, Nicolini J, et al: Brachytherapy of solid tumors. Use of chromic phosphate colloid. Acta Physiol Pharmacol Ther Latinoam. 47:179–185. 1997.(In Spanish).
18	Kang Y, Yin G, Ouyang P, et al: Preparation of PLLA/PLGA microparticles using solution enhanced dispersion by supercritical fluids (SEDS). J Colloid Interface Sci. 322:87–94. 2008. View Article : Google Scholar : PubMed/NCBI
19	Teupe C, Meffert R, Winckler S, et al: Ciprofloxacin-impregnated poly-L-lactic acid drug carrier. New aspects of a resorbable drug delivery system in local antimicrobial treatment of bone infections. Arch Orthop Trauma Surg. 112:33–35. 1992. View Article : Google Scholar : PubMed/NCBI
20	Pandey A and Aswath P: Indentation creep reservoirs for drug-eluting poly(L-lactic acid) scaffolds. J Biomater Sci Polym Ed. 22:1591–1606. 2011. View Article : Google Scholar : PubMed/NCBI
21	Yang M, Xu Y, Pan D, et al: Bioevaluation of a novel [32P]-CP-PLLA microparticle for pancreatic cancer treatment. Drug Dev Res. 71:364–370. 2010.
22	Finucane CM, Murray I, Sosabowski JK, et al: Quantitative accuracy of low-count SPECT imaging in phantom and in vivo mouse studies. Int J Mol Imaging. 2011:1973812011. View Article : Google Scholar : PubMed/NCBI
23	Cheng L, Jones TD, Lin H, et al: Lymphovascular invasion is an independent prognostic factor in prostate adenocarcinoma. J Urol. 174:2181–2185. 2005. View Article : Google Scholar : PubMed/NCBI
24	Gellman G, Healey G and Qingsheng C: The effect of very low dose irradiation on restenosis following balloon angioplasty. A study in the atherosclerotic rabbit. Circulation. 84(Suppl II): 46A–59A. 1991.